Hyderabad has received a significant boost with a $1 billion investment from Eli Lilly, a major US pharmaceutical company, to enhance its manufacturing and global medicine supply capabilities in the city.
This expansion will involve new contract manufacturing, leading to numerous job opportunities for the youth in Telangana.
The announcement followed a meeting between Eli Lilly’s global representatives and Chief Minister A Revanth Reddy and Industries Minister D. Sridhar Babu at the Integrated Command Control Centre on Monday.
The investment highlights the company’s confidence in Telangana’s leadership and governance. Despite interest from other states, Eli Lilly opted for Telangana due to its skilled workforce, infrastructure, and government support. This follows the opening of its global capability center in Hyderabad in August.
Eli Lilly’s investment goes beyond capability centers to focus on developing new medicines for conditions like diabetes, obesity, Alzheimer’s disease, cancer, and autoimmune disorders.
The company plans to start hiring soon, with positions available for engineers, chemists, analytical scientists, quality control and assurance professionals, and management roles. Once new facilities are set up, contract manufacturing will commence in Telangana for global distribution.
The Chief Minister expressed gratitude to Eli Lilly for choosing Telangana and promised complete government support for their upcoming projects. He credited Indira Gandhi’s initiative in 1965 with establishing IDPL, which transformed Hyderabad into a pharma hub. He noted that Hyderabad also played a crucial role in global Covid vaccine production.
